

# Trends and Practices in Early versus Late Initiation of Renal Replacement Therapy in South Korea and Taiwan

*Soie Kwon<sup>1, 2</sup>, Ping-Hsun Wu<sup>3</sup>, Yaerim Kim, Jeonghwan Lee,  
Dong Ki Kim, Yon Su Kim, Chun Soo Lim, Ming-Yen Lin, Yi-Wen Chiu<sup>3</sup>,  
Shang-Jyh Hwang<sup>3</sup>, Jung Pyo Lee*



# When to start RRT (Renal replacement therapy)

## <KDIGO 2024 Guideline>

### 5.4 Timing the initiation of dialysis

Practice Point 5.4.1: Initiate dialysis based on a composite assessment of a person's symptoms, signs, QoL, preferences, level of GFR, and laboratory abnormalities.

Practice Point 5.4.2: Initiate dialysis if the presence of **one or more of the following situations is evident** (Table 41). This often but not invariably occurs in the GFR range between 5 and 10 ml/min per  $1.73\text{ m}^2$ .



Practice Point 5.4.3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is  $<15\text{--}20\text{ ml/min per }1.73\text{ m}^2$  or risk of KRT is  $>40\%$  over 2 years.

**Table 41 | Indications for the initiation of dialysis**

**Symptoms or signs attributable to kidney failure** (e.g., neurological signs and symptoms attributable to uremia, pericarditis, anorexia, medically resistant acid-based or electrolyte abnormalities, intractable pruritus, serositis, and acid-base or electrolyte abnormalities)

**Inability to control volume status or blood pressure**


**Progressive deterioration in nutritional status refractory to dietary intervention, or cognitive impairment**




Cleveland Clinic  
©2022

# Different regulations RRT initiation

---



Each nephrologist is independently allowed to initiate RRT at their clinical discretion, when eGFR falls  $<15 \text{ mL/min/1.73 m}^2$



National insurance system generally restricts initiation to cases, where eGFR falls  $< 10 \text{ mL/min/1.73 m}^2$

- 1) Compares RRT initiation practices of South Korea and Taiwan, focusing on changes in the eGFR**
- 2) Whether the difference in RRT initiation timing is associated with the mortality difference**

# Cohort Population

- **South Korea**


- Two tertiary referral centers (SNUH, BRMH)
- 2001~2021

SNUH 서울대학교병원

SNUH 서울대학교병원 운영  
서울특별시보라매병원

- **Taiwan**

- One tertiary referral center (Taiwan Kidney Outcome (TAKO) cohort from Kaohsiung Medical University Hospital [KNUH] care system
- 2005 ~2021





# ► Comparison of baseline characteristics of two countries

Patients (N)	South Korea	Taiwan	Total	
	5,967	2,277	8,244	
Age (year)	60.0 [48.0;70.0]	65.0 [56.0;74.0]	61.0 [50.0;71.0]	<0.001
Body mass index	22.6 [20.4;25.1]	24.3 [21.7;27.2]	23.0 [20.7;25.7]	<0.001
Sex (male, %)	3508 (58.8%)	1239 (54.4%)	4747 (57.6%)	<0.001
<b>Comorbidities (N, %)</b>				
Diabetes mellitus	2781 (46.6%)	1546 (67.9%)	4327 (52.5%)	<0.001
Hypertension	3674 (61.6%)	2178 (95.7%)	5852 (71.0%)	<0.001
Dyslipidemia	887 (14.9%)	1097 (48.2%)	1984 (24.1%)	<0.001
Coronary artery disease	463 (7.8%)	412 (18.1%)	875 (10.6%)	<0.001
Heart failure	398 (6.7%)	634 (27.8%)	1032 (12.5%)	<0.001
<b>Laboratory findings</b>				
Blood urea nitrogen, mg/dL	68.0 [51.0;90.0]	102.3 [77.4;130.2]	75.0 [55.0;103.0]	<0.001
eGFR, ml/min/1.73m <sup>2</sup>	7.1 [5.2; 9.7]	3.9 [3.1; 5.0]	6.0 [4.2; 8.7]	<0.001
Albumin, g/L	3.6 [3.2; 4.0]	3.6 [3.2; 4.0]	3.6 [3.2; 4.0]	0.467
Hemoglobin, g/dL	9.7 [8.6;10.8]	9.0 [8.1;10.0]	9.5 [8.5;10.6]	<0.001
Potassium, mmol/L	4.8 [4.2; 5.4]	4.2 [3.8; 4.8]	4.6 [4.1; 5.2]	<0.001
Total CO <sub>2</sub> , mmol/L	20.0 [17.0;23.1]	19.4 [16.0;23.1]	20.0 [16.6;23.1]	<0.001
Glucose, mg/dL	107.0 [91.0;140.5]	104.0 [93.0;127.0]	106.0 [92.0;137.0]	0.002
Hemoglobin A1c, %	6.3 [5.7; 7.2]	6.0 [5.4; 6.8]	6.2 [5.6; 7.1]	<0.001
Phosphate, mg/dL	4.9 [4.1; 5.9]	5.7 [4.7; 7.0]	5.1 [4.2; 6.2]	<0.001
Total cholesterol, mg/dL	150.0 [125.0;180.0]	161.0 [133.0;193.0]	152.0 [126.9;183.0]	<0.001
UPCR, g/g	3.3 [1.7; 6.4]	3.6 [1.7; 6.7]	3.4 [1.7; 6.4]	0.129
Intact PTH	120.0 [52.0;246.0]	272.2 [150.4;443.4]	200.8 [98.3;378.0]	<0.001



Patients (N)	South Korea	Taiwan	Total	
	5,967	2,277	8,244	
<b>Medication usage</b>				
Anti-diabetic medications	1310 (22.0%)	1412 (62.0%)	2722 (33.0%)	<0.001
Metformin	95 (1.6%)	41 (1.8%)	136 (1.6%)	0.57
Sulfonylurea	573 (9.6%)	809 (35.5%)	1382 (16.8%)	<0.001
DPP4-inhibitor	487 (8.2%)	745 (32.7%)	1232 (14.9%)	<0.001
TZD	98 (1.6%)	96 (4.2%)	194 (2.4%)	<0.001
Insulin	568 (9.5%)	1077 (47.3%)	1645 (20.0%)	<0.001
Anti-hypertensive medications	3473 (58.2%)	2154 (94.6%)	5627 (68.3%)	<0.001
RAS Blocker	2702 (45.3%)	1426 (62.6%)	4128 (50.1%)	<0.001
Diuretics	1664 (27.9%)	1796 (78.9%)	3460 (42.0%)	<0.001
Statin	1983 (33.2%)	1137 (49.9%)	3120 (37.8%)	<0.001





# ► Differences in eGFR Trends Between South Korea and Taiwan



# ► Subgroup analysis (1) Age




## ► Subgroup analysis (2) Other comorbidities




## ► 5 Year Mortality – Kaplan Meier



1457/5967 = 24.4%



658/2777 = 28.9%



## ► 5 Year Mortality – Cox analysis


		eGFR 10≤ <15			eGFR 5≤ <10			eGFR<5		
		HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Korea	Univariate	1.024	0.9037-1.1602	0.71	1	Ref		0.765	0.6673-0.8757	<0.001
	Model 1	0.978	0.8629-1.1092	0.7325				0.927	0.8082-1.0641	0.2827
	Model 2	1.018	0.8943-1.582	0.7894				0.904	0.7828-1.0443	0.1704
	Model 3	1.014	0.8912-1.1542	0.8306				0.921	0.7968-1.0639	0.2626
Taiwan	Univariate	Data were excluded due to lack of representativeness			1	Ref		0.440	0.3749-0.5157	<0.001
	Model 1							0.555	0.4702-0.6541	<0.001
	Model 2							0.528	0.4253-0.6555	<0.001
	Model 3							0.533	0.4293-0.6626	<0.001

Model 1 : Gender, Age, Hospital, Year, DM, HTN, DL


Model 2 : Model 1 + Laboratory (BUN, Albumin, Hb, Phosphate, Total cholesterol)

Model 3 : Model 2 + + Medication (DM med, HTN med, Diuretics, Statin)


Reference: Korea, eGFR 5≤ <10, Cox Model 3



# ► 5 Year Mortality – Propensity score matching with Cox



Sample  
● Unadjusted  
● Adjusted



## ► Conclusion

---

- RRT was initiated earlier in Korea compared to Taiwan
- Taiwan has maintained a stable eGFR threshold for dialysis initiation due to government regulations, whereas Korea has shown a trend toward earlier initiation in recent years
- Even after adjustment using Cox regression and PSM, Korean patients with eGFR 5–10 at dialysis initiation show better survival.

► This suggests that, for patients with eGFR 10–15, earlier dialysis initiation based on clinical judgment may potentially improve survival.



## ► Limitations


---

- This retrospective observational study has limitations
  - Three-center design limits generalizability to national level
  - Lack of data on uremic symptoms (a key factor for dialysis initiation)
  - Inability to assess differences by RRT modality comparison
  - Unable to confirm whether pre-RRT preparation for modality was performed
  - Possible residual bias beyond RRT start timing that may explain higher survival in Korean patients





Thank you  
for your attention



중앙대학교병원  
CHUNG-ANG UNIVERSITY HOSPITAL